COMT and Parkinson disease: Ninety-four patients (26.6%) were on l-dopa (or l-dopa derivative) monotherapy, whereas 259 (73.2%) were receiving ≥2 PD medications (including l-dopa for all patients) in any combination (primarily dopamine agonists [55.4% of all patients], amantadine [29.9%], and catechol-O-methyltransferase (COMT) inhibitors [28.2%]), all of which were discontinued before LCIG treatment.